Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-06
2009-10-27
Bunner, Bridget E (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900, C530S300000
Reexamination Certificate
active
07608691
ABSTRACT:
The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 6159463 (2000-12-01), Center et al.
patent: 6444202 (2002-09-01), Kurth et al.
patent: 6699466 (2004-03-01), Center et al.
patent: WO 94/28134 (1994-12-01), None
patent: WO 99/37781 (1999-07-01), None
patent: WO 99/48514 (1999-09-01), None
Hessel et al. Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 160: 2298, 1998.
Keane et al. Conservation of structure and function between human and murine IL-16. J Immunol 160: 5945-5954, 1998.
Yoshimoto et al. Role of IL-16 in delayed-type hypersensitivity reaction. Blood 95(9): 2869-2874, 2000.
Cruikshank et al. Interleukin-16. J Leukocyte Biol 67(6): 757-766, 2000.
Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol. 28(11):1171-1181, 1991.
Li et al. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities.Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Skolnick et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era”,Trends in Biotech, 18(1):34-39 (2000).
Bork, A., “Powers and Pitfalls in Sequence Analysis: the 70% Hurdle”,Genome Res, 10:398-400 (2000).
Doerks et al.“Protein Annotation: Detective Work for Function Prediction”,Trends in Genetics, 14(6):248-250 (1998).
Smith et al., The Challenges of Genome Sequence Annotation or “The Devil is in the Details”,Nature Biotech, 15:1222-1223 (1997).
Brenner, S. E., “Errors in Genome Function”,Trends in Genetics, 15(4):132-133 (1999).
Bork et al., “Go Hunting in Sequence Databases But Watch Out for the Traps”Trends in Genetics, 12(10):425-427 (1996).
Wells, J. A., “Additivity of Mutational Effects in Proteins”,Biochemistry, 29(37):8509-8517 (1990).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”,The Protein Folding Problem and Tertiary Structure Prediction, 492-495 (1994).
Center et al., “Modulation of Lymphocyte Migration of Human Lymphokines; Identification and Characterization of Chemoattractant Activity for Lymhocytes from Mitogen-Stimulated Mononuclear Cells”,J Immunol, 128(6):2563-2568 (1982).
Cruikshank et al., “Molecular and Functional Analysis of a Lymphocyte Chemoattractant Factor: Association of Biologic Function with CD4 Expression”,Proc Natl Acad Sci USA, 91:5109-5113 (1994).
Cruikshank et al., “Lymphocyte Chemoattractant Factor Induces CD4-Dependent Intracytoplasmic Signaling in Lymphocytes”,J Immunol, 146: 2928-2934 (1991).
Cruikshank et al., “Biological Activity of Interleukin-16”,Nature, 382(6591):501-502 (1996).
Nicoll et al., “Identification of Domains in IL-16 Critical for Biological Activity”,J Immunol, 163:1827-1832 (1999).
Liu et al., “Identification of a CD4 Domain Required for Interleukin-16 Binding and Lymphocyte Activation”,J Biol Chem, 274(33):23387-23395 (1999).
de Bie et al., “Effects of Interleukin-16-Blocking Peptide on Parameters of Allergic Asthma in a Murine Model”,Eur J Pharmacol, 383:189-196 (1999).
IUIS/WJO Standing Committee on Interleukin Designation “Interleukin 16”,Eur J Immunol, 26:1196(1995).
Center David M.
Cruikshank William W.
Kornfeld Hardy
Bunner Bridget E
Scully , Scott, Murphy & Presser, P.C.
Trustees of Boston University
LandOfFree
Antibodies against IL-16 antagonist peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against IL-16 antagonist peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against IL-16 antagonist peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062427